SEC Form 4 · accession 0001628280-26-061836
Amneal Pharmaceuticals, Inc. · AMRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
J Kevin Buchi
Director
Period of report
Sep 11, 2026
Accepted (ET)
Sep 14, 2026 · 4:10 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001723128
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Class A Common Stock | Sep 11, 2026 | M | 20,445 | $14.45 | A | 95,522 | D | |
| Class A Common Stock | holding | — | — | — | 93,499 | I | By Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF1 | $14.45 | Sep 11, 2026 | M | 20,445 | D | — | Nov 23, 2026 | Class A Common Stock | 20,445 | 0 | D |
Explanation of responses
- F1The option is vested and currently exercisable.